Optimizing the antitumor selectivity of PVP-Hypericin re A549 cancer cells and HLF normal cells through pulsed blue light

Photodiagnosis and Photodynamic Therapy

Volumn 10, Issue 4, 2013, Pages 591-599

  Penjweini, Rozhin ^a,b   Loew, Hans G ^a,c   Breit, Paul ^c   Kratky, Karl W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b HASSELT UNIVERSITY   (Belgium)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

A549 cancer cells; HLF normal cells; PVP Hypericin; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYFLUORESCEIN DIACETATESUCCINIMIDYL ESTER; FLUORESCENT DYE; HYPERICIN; POVIDONE; SINGLET OXYGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLUE LIGHT; CAMERA; CANCER CELL; CELL CULTURE; COLLIMATOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIRECT CURRENT; FLUORESCENCE; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; HYPOTHESIS; IMAGING SOFTWARE; IN VITRO STUDY; IRRADIATION; LIGHT EMITTING DIODE; LUNG CARCINOMA; LUNG FIBROBLAST; PHOTOREACTIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; RADIATION ENERGY; THERAPY; TIME LAPSE IMAGING;

A549 CANCER CELLS; HLF NORMAL CELLS; PVP-HYPERICIN; SIDE-EFFECTS;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG CARRIERS; HUMANS; LUNG NEOPLASMS; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POVIDONE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84888059378     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2013.06.005     Document Type: Article

References (24)

1. Vandepitte J., Van Poppel H., De Witte P.A. PVP-Hypericin as a photodiagnostic and phototherapeutic tool for bladder cancer: a preclinical study. Belgian Journal of Medical Oncology 2010, 4:261-263.
2. Kang C.C., Chen C.T., Cho C.C., Lin Y.C., Chang C.C., Chang T.C. A dual selective antitumor agent and fluorescence probe: the binary BMVC-porphyrin photosensitizer. ChemMedChem 2008, 3:725-728.
3. 6 enhances its photosensitizing activity. The Journal of Biological Chemistry 1997, 272:20328-20331.
4. Rosenkranz A.A., Jans D.A., Sobolev A.S. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunology and Cell Biology 2000, 78:452-464.
5. Dysart J.S., Patterson M.S., Farrell T.J., Singh G. Relationship between mTHPC fluorescence photobleaching and cell viability during in vitro photodynamic treatment of DP16 cells. Photochemistry and Photobiology 2002, 75:289-295.
6. Kogan B.Y. Nonlinear photodynamic therapy. Saturation of a photochemical dose by photosensitizer bleaching. Photochemical & Photobiological Sciences 2003, 2:673-676.
7. Chen K., Preuß A., Hackbarth S., Wacker M., Langer K., Röder B. Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations. Journal of Photochemistry and Photobiology B: Biology 2009, 96:66-74.
8. Beyer W. Systems for light application and dosimetry in photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology 1996, 36:153-156.
9. Theodossiou T.A., Hothersall J.S., De Witte P.A., Pantos A., Agostinis P. The multifaceted photocytotoxic profile of Hypericin. Molecular Pharmaceutics 2009, 6:1775-1789.
10. Eriksson E.S.E., dos Santos D.J.V.A., Guedes R.C., Eriksson L.A. Properties and permeability of Hypericin and brominated Hypericin in lipid membranes. Journal of Chemical Theory and Computation 2009, 5:3139-3149.
11. Kubin A., Loew H.G., Burner U., Jessner G., Kolbabek H., Wierrani F. How to make Hypericin water-soluble. Pharmazie 2008, 63:263-269.
12. Penjweini R., Loew H.G., Hamblin M.R., Kratky K.W. Long-term monitoring of live cell proliferation in presence of PVP-Hypericin: a new strategy using ms pulses of LED and the fluorescent dye CFSE. Journal of Microscopy 2012, 245:100-108.
13. Penjweini R., Loew H.G., Eisenbauer M., Kratky K.W. Modifying excitation light dose of novel photosensitizer PVP-Hypericin for photodynamic diagnosis and therapy. Journal of Photochemistry and Photobiology B: Biology 2013, 120:120-129.
14. García-Díaz M., Nonell S., Villanueva Á., Stockert J.C., Cañete M., Casadó A., et al. Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity?. Biochimica et Biophysica Acta 2011, 1808:1063-1071.
15. Maisch T., Moor A.C.E., Regensburger J., Ortland C., Szeimies R.M., Bäumler W. Intense pulse light and 5-ALA PDT: phototoxic effects in vitro depend on the spectral overlap with protoporphyrine IX but do not match cut-off filter notations. Lasers in Surgery and Medicine 2011, 43:176-182.
16. Henning J.P., Fournier R.L., Hampton J.A. A transient mathematica model of oxygen depletion during photodynamic therapy. Radiation Research 1995, 142:221-226.
17. Qi J., Ding Y., Zhu Y., Wu Y. Kinetic theory approach to modeling of cellular repair mechanisms under genome stress. PLoS ONE 2011, 6:e22228.
18. Miller C.S., Smith K.O. Enhanced replication of herpes simplex virus type 1 in human cells. Journal of Dental Research 1991, 70:111-117.
19. Manda G., Nechifor M.T., Neagu T.-M. Reactive oxygen species, cancer and anti-cancer therapies. Current Chemical Biology 2009, 3:342-366.
20. Quah B.J.C., Warren H.S., Parish C.R. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nature Protocols 2007, 2:2049-2056.
21. Vandepitte J., Van Cleynenbreugel B., Hettinger K., Van Poppel H., de Witte P.A.M. Biodistribution of PVP-Hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder. Cancer Chemotherapy and Pharmacology 2011, 67:775-781.
22. Liu J., Lay Lay Saw C., Olivo M., Sudhaharan T., Ahmed S., Wan Sia Heng P., et al. Study of interaction of Hypericin and its pharmaceutical preparation by fluorescence techniques. Journal of Biomedical Optics 2009, 14:014003.
23. Casciola-Rosen L., Rosen A., Petri M., Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:1624-1629.
24. Van Engeland M., Ramaekers F.C., Schutte B., Reutelingsperger C.P. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996, 24:131-139.